ESMO Members: Survey on Incidence of Organ Rejection in Cancer Patients

  • Date: 03 Nov 2017

Incidence of Organ Rejection in Cancer Patients with an Organ Transplant and Treated with Immune Checkpoints Inhibitors

The primary objective of the survey is to measure the number of organ transplanted patients and the incidence of organ rejection in these transplanted patients treated for their cancer with Immune Check Point Inhibitors.

Individuals with a transplanted organ have an increased incidence of developing malignant tumours, mainly skin epitheliomas and hemopathies, less frequently other common adult tumours.

Their exposure to prolonged immunosuppression is the main factor responsible for the increased incidence of cancer.

With the development of Immunotherapy using Immune Check Point Inhibitors (anti- PD1/PDL1 or CTLA-4) to abrogate tumour-induced immunosuppression, many cancer patients are being exposed to or may be considered for treatment with these drugs, including patients with organ or Allogeneic Peripheral Stem Cell Transplantation. Due to the mode of action, inducing or augmenting a cancer-specific immune response, there is a risk of organ rejection in organ transplanted patients and a few cases have been reported in the literature.

This survey, opened to all Members worldwide, aims at capturing the magnitude of this particular problem.

Answer the Survey on Incidence of Organ Rejection in Cancer Patients